Hepatology and liver failure
Clinical research includes care for decompensated cirrhosis, with attention to long-term albumin treatment and the safety of alternative albumin formulations in advanced liver disease.
- Decompensated cirrhosis
- Albumin replacement therapy
- Advanced chronic liver disease
The sponsor also studies unresectable hepatocellular carcinoma, including patients with early progression after first-line systemic treatment.
Oncologic imaging and diagnostic clarification
Research activity covers patients with suspected or newly diagnosed oncological disease when standard diagnostic pathways leave uncertainty, with emphasis on advanced PET/CT approaches.
- 68Ga-FAPI PET/CT
- 18F-FDG PET/CT
- Diagnostic uncertainty in cancer
This area reflects interest in improving lesion detection and clarifying equivocal imaging findings across complex oncology cases.
Hepatobiliary oncology and treatment-resistant disease
The sponsor funds studies in hepatocellular carcinoma focused on patients whose disease is not controlled by standard first-line therapy, with interest in additional modalities for resistant tumor behavior.
- Unresectable hepatocellular carcinoma
- Therapy-resistant progression
- Multimodal cancer care
Research in this field is directed toward advanced liver cancer management in a setting of limited treatment options.
Gynecologic oncology
Clinical trials include women with relapsing vulvar carcinoma after prior surgery and radiation-based treatment, addressing recurrent disease in a difficult-to-treat malignancy.
- Vulvar carcinoma
- Recurrent gynecologic cancer
- Local disease control
This research area reflects a focus on salvage strategies for recurrent gynecologic malignancies.
Endocrinology and adrenal disorders
Another area of interest is subclinical and mild Cushing’s syndrome in patients with adrenal incidentalomas, with evaluation of blood pressure and cardiovascular-related outcomes.
- Adrenal incidentalomas
- Subclinical Cushing’s syndrome
- Hypertension in adrenal disease
These studies connect endocrine evaluation with management of cardiometabolic risk in adrenal pathology.
